N6-(2-bromobenzyl)-N4-(5-methyl-1H-pyrazol-3-yl)-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine

ID: ALA5208535

PubChem CID: 168294383

Max Phase: Preclinical

Molecular Formula: C16H15BrN8

Molecular Weight: 399.26

Names and Identifiers

Canonical SMILES:  Cc1cc(Nc2nc(NCc3ccccc3Br)nc3[nH]ncc23)n[nH]1

Standard InChI:  InChI=1S/C16H15BrN8/c1-9-6-13(24-23-9)20-14-11-8-19-25-15(11)22-16(21-14)18-7-10-4-2-3-5-12(10)17/h2-6,8H,7H2,1H3,(H4,18,19,20,21,22,23,24,25)

Standard InChI Key:  QBAVYNAZOYZQRG-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 25 28  0  0  0  0  0  0  0  0999 V2000
   -1.4334   -0.0345    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7188    0.3777    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0069   -0.0340    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0069   -0.8593    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7170   -1.2711    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4334   -0.8630    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.2407   -1.1141    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.7134   -0.4579    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.2194    0.2123    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7076   -1.2718    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.4223   -0.8593    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.1369   -1.2718    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.8517   -0.8594    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.5638   -1.2714    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.5638   -2.0968    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.8536   -2.5088    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.1369   -2.1005    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7188    1.2030    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4334    1.6155    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1480    1.2030    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.7667    1.7743    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.4361    2.5088    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.6119    2.4165    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.5638    1.5607    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.8517   -0.0342    0.0000 Br  0  0  0  0  0  0  0  0  0  0  0  0
  2  1  2  0
  3  2  1  0
  4  3  2  0
  5  4  1  0
  6  5  2  0
  1  6  1  0
  6  7  1  0
  7  8  1  0
  9  8  2  0
  1  9  1  0
  4 10  1  0
 10 11  1  0
 11 12  1  0
 13 12  2  0
 14 13  1  0
 15 14  2  0
 16 15  1  0
 17 16  2  0
 12 17  1  0
  2 18  1  0
 18 19  1  0
 20 19  1  0
 20 21  2  0
 21 22  1  0
 23 22  1  0
 19 23  2  0
 21 24  1  0
 13 25  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA5208535

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 399.26

Molecular Weight (Monoisotopic): 398.0603

AlogP: 3.50

#Rotatable Bonds: 5

Polar Surface Area: 107.20

Molecular Species: NEUTRAL

HBA: 6

HBD: 4

#RO5 Violations: ┄

HBA (Lipinski): 8

HBD (Lipinski): 4

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 8.89

CX Basic pKa: 3.43

CX LogP: 3.52

CX LogD: 3.50

Aromatic Rings: 4

Heavy Atoms: 25

QED Weighted: 0.41

Np Likeness Score: -1.86

References

1. Sun Y, Sun Y, Wang L, Wu T, Yin W, Wang J, Xue Y, Qin Q, Sun Y, Yang H, Zhao D, Cheng M..  (2022)  Design, synthesis, and biological evaluation of novel pyrazolo [3,4-d]pyrimidine derivatives as potent PLK4 inhibitors for the treatment of TRIM37-amplified breast cancer.,  238  [PMID:35576702] [10.1016/j.ejmech.2022.114424]

Source

Source(1):

• Scientific Literature